Committed to serving the COPD community, AstraZeneca’s BREZTRI team is unveiling their latest, direct-to-consumer US advertising campaign, “Get Real.”
Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital launched a joint laboratory to research new drugs to treat chronic lung diseases.
Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration approved the New Drug Application for Lonhala Magnair (glycopyrrolate) Inhalation Solution (25 mcg twice daily) – also known as SUN-101/eFlow – for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.
Chiesi Group announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for the extrafine triple combination ICS/LABA/LAMA, under the brand name Trimbow, for the first time in a single inhaler for the treatment of Chronic Obstructive Pulmonary Disease.
